CMS finalized the mandatory GLOBE model, linking Medicare Part B rebates to international drug prices starting in 2027. See ...

Foghorn Therapeutics is cutting about 40% of its workforce after ending FHD-909 and other SMARCA2 programs with Lilly. Read ...

Atara Biotherapeutics resubmits tabelecleucel BLA to FDA for EBV+ post-transplant lymphoproliferative disease. Latest updates ...

Progentos begins Phase I/II human trial of oral PRO-1562 for multiple sclerosis remyelination. First-in-human study ...

Regeneron and Sanofi expand antibody alliance with $1B upfront and $7B in milestones for IL-4/IL-13 pathway treatments. Learn ...